Edition:
United States

Opiant Pharmaceuticals Inc (OPNT.OQ)

OPNT.OQ on NASDAQ Stock Exchange Capital Market

22.55USD
15 Dec 2017
Change (% chg)

$-0.95 (-4.04%)
Prev Close
$23.50
Open
$23.00
Day's High
$23.75
Day's Low
$22.55
Volume
29,791
Avg. Vol
--
52-wk High
$51.90
52-wk Low
$21.35

Latest Key Developments (Source: Significant Developments)

Opiant Pharmaceuticals, Inc. Reports Qtrly ‍net Loss Per Common Share $2.77​
Monday, 4 Dec 2017 04:05pm EST 

Dec 4 (Reuters) - Opiant Pharmaceuticals Inc ::OPIANT PHARMACEUTICALS, INC. REPORTS FISCAL FIRST QUARTER 2018 FINANCIAL RESULTS.OPIANT PHARMACEUTICALS INC - QTRLY ‍NET LOSS PER COMMON SHARE $2.77​.  Full Article

Opiant pharmaceuticals says ‍may offer & sell its shares through Cantor Fitzgerald
Thursday, 19 Oct 2017 07:12am EDT 

Oct 19 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals says ‍may offer & sell through Cantor Fitzgerald its shares having aggregate offering price of up to $25 million - SEC filing​.  Full Article

Opiant Pharmaceuticals files for mixed shelf of upto $150 mln
Monday, 16 Oct 2017 03:25pm EDT 

Oct 16 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals Inc files for mixed shelf of upto $150 million - sec filing ‍​.  Full Article

Opiant Pharmaceuticals reports Q4 loss per share $0.17‍​
Friday, 13 Oct 2017 07:00am EDT 

Oct 13 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals Inc reports fiscal fourth quarter and full year 2017 financial results and provides corporate update.Q4 revenue $3.75 million versus $300,000.‍Opiant Pharmaceuticals Inc - appointed David O'Toole as chief financial officer​.Opiant Pharmaceuticals Inc - qtrly loss per share $0.17‍​.  Full Article

Opiant Pharma, Titan Pharmac to explore new treatments for opioid abuse
Monday, 2 Oct 2017 07:00am EDT 

Oct 2 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals and Titan Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment.Opiant Pharma - co, Titan will conduct feasibility assessment of a subcutaneous implant using titan's proprietary proneura sustained release technology.  Full Article

Opiant Pharmaceuticals Inc provides an update on Narcan nasal spray
Friday, 15 Sep 2017 07:00am EDT 

Sept 15 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals Inc provides an update on Narcan nasal spray.Opiant Pharmaceuticals Inc - ‍Adapt has maintained price of Narcan nasal spray, including a discounted public interest price of $75 per two-dose pack​.Opiant Pharmaceuticals Inc says ‍in over 40 states, Narcan nasal spray can now be purchased from pharmacies without a prescription​.Opiant Pharmaceuticals - ‍Narcan surpasses $25 million of net sales for H1 calendar 2017, triggering SWK Funding Llc's obligation to pay co additional $3.75 million​.  Full Article

Opiant Pharmaceuticals says co and Torreya Partners entered into a supplemental engagement letter
Thursday, 14 Sep 2017 05:14pm EDT 

Sept 15 (Reuters) - Opiant Pharmaceuticals Inc :Opiant Pharmaceuticals Inc - ‍on September 8, co and Torreya Partners entered into a supplemental engagement letter effective September 7​.Opiant Pharmaceuticals Inc - ‍supplemental agreement modifies and supplements engagement letter dated December 18, 2014.​.  Full Article

Opiant Pharmaceuticals announces appointment of David O’Toole as CFO
Tuesday, 5 Sep 2017 07:00am EDT 

Sept 5 (Reuters) - Opiant Pharmaceuticals Inc ::Opiant Pharmaceuticals Inc announces appointment of David O’Toole as chief financial officer.Opiant Pharmaceuticals says David O'Toole will succeed Kevin Pollack, co's outgoing CFO, who will be stepping down on September 11, 2017​.  Full Article

Opiant Pharmaceuticals Q3 earnings per share $0.15
Thursday, 9 Jun 2016 08:00am EDT 

Opiant Pharmaceuticals Inc : Opiant pharmaceuticals, inc. Reports fiscal third quarter 2016 financial results and provides corporate update .Q3 earnings per share $0.15.  Full Article